Brighton Jones LLC Acquires Shares of 1,694 Quest Diagnostics Incorporated (NYSE:DGX)

Brighton Jones LLC acquired a new stake in shares of Quest Diagnostics Incorporated (NYSE:DGX) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 1,694 shares of the medical research company’s stock, valued at approximately $234,000.

Several other institutional investors and hedge funds have also bought and sold shares of DGX. NBC Securities Inc. bought a new position in Quest Diagnostics during the third quarter valued at $25,000. VisionPoint Advisory Group LLC lifted its position in shares of Quest Diagnostics by 100.0% during the third quarter. VisionPoint Advisory Group LLC now owns 218 shares of the medical research company’s stock worth $27,000 after acquiring an additional 109 shares in the last quarter. BKM Wealth Management LLC purchased a new stake in shares of Quest Diagnostics during the fourth quarter worth $29,000. FinTrust Capital Advisors LLC boosted its stake in Quest Diagnostics by 1,100.0% in the 3rd quarter. FinTrust Capital Advisors LLC now owns 264 shares of the medical research company’s stock worth $32,000 after purchasing an additional 242 shares during the period. Finally, Alaska Permanent Fund Corp grew its holdings in Quest Diagnostics by 79.3% during the 4th quarter. Alaska Permanent Fund Corp now owns 242 shares of the medical research company’s stock valued at $33,000 after buying an additional 107 shares in the last quarter. 88.06% of the stock is owned by institutional investors.

Quest Diagnostics Trading Up 0.8 %

Shares of DGX opened at $137.38 on Friday. Quest Diagnostics Incorporated has a fifty-two week low of $119.59 and a fifty-two week high of $145.58. The firm has a market cap of $15.26 billion, a price-to-earnings ratio of 18.49, a PEG ratio of 2.96 and a beta of 0.88. The firm has a 50 day moving average price of $130.33 and a 200-day moving average price of $131.71. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.89 and a current ratio of 0.97.

Quest Diagnostics (NYSE:DGX) last posted its quarterly earnings results on Tuesday, April 23rd. The medical research company reported $2.04 earnings per share for the quarter, topping the consensus estimate of $1.86 by $0.18. The business had revenue of $2.37 billion during the quarter, compared to the consensus estimate of $2.29 billion. Quest Diagnostics had a net margin of 9.11% and a return on equity of 15.52%. The firm’s revenue for the quarter was up 1.7% on a year-over-year basis. During the same period in the previous year, the firm posted $2.04 earnings per share. As a group, equities research analysts forecast that Quest Diagnostics Incorporated will post 8.78 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the stock. Barclays raised their price objective on shares of Quest Diagnostics from $138.00 to $144.00 and gave the company an “equal weight” rating in a research report on Thursday, April 25th. Truist Financial upped their price target on shares of Quest Diagnostics from $145.00 to $150.00 and gave the stock a “hold” rating in a report on Wednesday, April 24th. StockNews.com cut Quest Diagnostics from a “buy” rating to a “hold” rating in a research report on Friday. UBS Group raised their price target on Quest Diagnostics from $139.00 to $146.00 and gave the company a “neutral” rating in a report on Wednesday, April 24th. Finally, Jefferies Financial Group raised Quest Diagnostics from a “hold” rating to a “buy” rating and boosted their price objective for the stock from $140.00 to $155.00 in a report on Wednesday, February 7th. Ten investment analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $146.17.

Insiders Place Their Bets

In other Quest Diagnostics news, Director Vicky B. Gregg sold 2,500 shares of the business’s stock in a transaction on Friday, February 23rd. The shares were sold at an average price of $126.64, for a total value of $316,600.00. Following the completion of the sale, the director now directly owns 16,329 shares of the company’s stock, valued at $2,067,904.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Quest Diagnostics news, EVP Catherine T. Doherty sold 821 shares of the business’s stock in a transaction on Thursday, February 22nd. The shares were sold at an average price of $126.14, for a total value of $103,560.94. Following the completion of the sale, the executive vice president now directly owns 70,800 shares of the company’s stock, valued at $8,930,712. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Vicky B. Gregg sold 2,500 shares of the business’s stock in a transaction on Friday, February 23rd. The stock was sold at an average price of $126.64, for a total transaction of $316,600.00. Following the completion of the sale, the director now directly owns 16,329 shares of the company’s stock, valued at $2,067,904.56. The disclosure for this sale can be found here. Insiders sold 16,910 shares of company stock valued at $2,159,602 over the last three months. Insiders own 0.79% of the company’s stock.

Quest Diagnostics Profile

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.